Stewart D J, Mikhael N Z, Nair R C, Kacew S, Montpetit V, Nanji A, Maroun J A, Howard K
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
Am J Clin Oncol. 1988 Apr;11(2):152-8. doi: 10.1097/00000421-198804000-00013.
Platinum concentrations were determined in autopsy tumor samples obtained from 27 patients who had received cisplatin 40-1,029 mg/m2 from 0 to 240 days antemortem. Liver metastases had significantly higher platinum concentrations than did tumors in other sites (p less than 0.005). Platinum concentrations in liver metastases were similar to platinum concentrations in normal liver. Platinum concentrations in gliomas and brain metastases were similar to platinum concentrations in other extrahepatic tumors. Platinum concentration generally decreased with increasing distance into brain from tumor. By multiple stepwise linear regression analysis, the factors that were independently most closely associated with tumor platinum concentration were time from last cisplatin treatment, cumulative lifetime dose of cisplatin, route of cisplatin administration (intraarterial vs. other), and site of tumor deposit (liver vs. other) (r = 0.69, p less than 0.001). Patients whose tumors had responded to cisplatin-containing regimens had mean tumor platinum concentrations that were higher than the mean tumor platinum concentrations in patients whose tumors had not responded to cisplatin (p less than 0.05).
对27例在死前0至240天接受了40 - 1029mg/m²顺铂治疗的患者的尸检肿瘤样本进行了铂浓度测定。肝转移瘤的铂浓度显著高于其他部位的肿瘤（p<0.005）。肝转移瘤中的铂浓度与正常肝脏中的铂浓度相似。胶质瘤和脑转移瘤中的铂浓度与其他肝外肿瘤中的铂浓度相似。铂浓度通常随着距肿瘤进入脑内距离的增加而降低。通过多元逐步线性回归分析，与肿瘤铂浓度独立最密切相关的因素是距末次顺铂治疗的时间、顺铂的累积终身剂量、顺铂给药途径（动脉内给药与其他途径）以及肿瘤沉积部位（肝脏与其他部位）（r = 0.69，p<0.001）。肿瘤对含顺铂方案有反应的患者的肿瘤铂平均浓度高于肿瘤对顺铂无反应的患者的肿瘤铂平均浓度（p<0.05）。
